DCP2

Across TCGA pan-cancer cohorts, DCP2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DCP2 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DCP2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated DCP2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where DCP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.448	0.616	.006	10	view →
HNSC	OS	Median	All	1.000	0.944	.014	4	view →
LUAD	DFS	Median	III,IV	0.432	0.925	.047	3	view →
CCRCC	DFS	Quartile	All	1.000	0.812	.019	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DCP2–PDAC (OS)

Open the PDAC breakdown →